Peregrine Capital Management LLC Lowers Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

Peregrine Capital Management LLC reduced its stake in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 14.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 306,558 shares of the technology company's stock after selling 52,230 shares during the period. Peregrine Capital Management LLC owned 0.27% of Evolent Health worth $10,126,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in EVH. American Century Companies Inc. lifted its position in shares of Evolent Health by 12.7% during the 1st quarter. American Century Companies Inc. now owns 20,453 shares of the technology company's stock valued at $661,000 after buying an additional 2,300 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Evolent Health during the 1st quarter valued at about $296,000. MetLife Investment Management LLC lifted its position in shares of Evolent Health by 52.2% during the 1st quarter. MetLife Investment Management LLC now owns 44,172 shares of the technology company's stock valued at $1,427,000 after buying an additional 15,143 shares in the last quarter. BlackRock Inc. lifted its position in shares of Evolent Health by 4.9% during the 1st quarter. BlackRock Inc. now owns 6,180,992 shares of the technology company's stock valued at $199,644,000 after buying an additional 291,029 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Evolent Health by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,657,874 shares of the technology company's stock worth $247,350,000 after purchasing an additional 111,882 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently commented on EVH. JMP Securities boosted their price target on Evolent Health from $37.00 to $38.00 and gave the stock a "market outperform" rating in a report on Friday, February 23rd. William Blair reissued an "outperform" rating on shares of Evolent Health in a report on Tuesday, January 9th. Oppenheimer began coverage on Evolent Health in a report on Friday, March 1st. They issued an "outperform" rating and a $45.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on Evolent Health from $53.00 to $52.00 and set an "overweight" rating on the stock in a report on Friday, March 15th. Finally, Barclays assumed coverage on Evolent Health in a research note on Wednesday, January 3rd. They issued an "overweight" rating and a $39.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.70.

Evolent Health Trading Up 2.3 %

Shares of NYSE EVH traded up $0.70 during trading hours on Tuesday, hitting $31.20. 970,409 shares of the company traded hands, compared to its average volume of 981,525. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of -24.57 and a beta of 1.54. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company's 50 day moving average price is $31.95 and its 200 day moving average price is $30.06. Evolent Health, Inc. has a 12 month low of $23.33 and a 12 month high of $36.70.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.13. The firm had revenue of $556.06 million for the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. On average, equities research analysts anticipate that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.